Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.13EUR
−485.60 MEUR
1.13 BEUR
88.80 M
About Sarepta Therapeutics, Inc.
Sector
CEO
Douglas S. Ingram
Headquarters
Cambridge
Website
Employees (FY)
1.31 K
Founded
1980
FIGI
BBG000C98T59
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where AB3A is featured.
Frequently Asked Questions
The current price of AB3A is 147.80 EUR — it has increased by 0.07% in the past 24 hours. Watch SAREPTA THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SAREPTA THERAPEUTICS INC stocks are traded under the ticker AB3A.
AB3A stock has fallen by 3.24% compared to the previous week, the month change is a 41.64% rise, over the last year SAREPTA THERAPEUTICS INC has showed a 43.08% increase.
We've gathered analysts' opinions on SAREPTA THERAPEUTICS INC future price: according to them, AB3A price has a max estimate of 220.04 EUR and a min estimate of 138.58 EUR. Watch AB3A chart and read a more detailed SAREPTA THERAPEUTICS INC stock forecast: see what analysts think of SAREPTA THERAPEUTICS INC and suggest that you do with its stocks.
AB3A reached its all-time high on Jun 21, 2024 with the price of 160.95 EUR, and its all-time low was 2.81 EUR and was reached on Jul 24, 2012. View more price dynamics on AB3A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AB3A stock is 1.33% volatile and has beta coefficient of 0.03. Track SAREPTA THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is SAREPTA THERAPEUTICS INC there?
Today SAREPTA THERAPEUTICS INC has the market capitalization of 13.95 B, it has increased by 39.53% over the last week.
Yes, you can track SAREPTA THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
SAREPTA THERAPEUTICS INC is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
AB3A earnings for the last quarter are 0.34 EUR per share, whereas the estimation was 0.01 EUR resulting in a 2.77 K% surprise. The estimated earnings for the next quarter are −0.12 EUR per share. See more details about SAREPTA THERAPEUTICS INC earnings.
SAREPTA THERAPEUTICS INC revenue for the last quarter amounts to 383.19 M EUR, despite the estimated figure of 351.73 M EUR. In the next quarter, revenue is expected to reach 368.34 M EUR.
AB3A net income for the last quarter is 33.47 M EUR, while the quarter before that showed 41.36 M EUR of net income which accounts for −19.07% change. Track more SAREPTA THERAPEUTICS INC financial stats to get the full picture.
No, AB3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 30, 2024, the company has 1.31 K employees. See our rating of the largest employees — is SAREPTA THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SAREPTA THERAPEUTICS INC EBITDA is −35.00 M EUR, and current EBITDA margin is −16.80%. See more stats in SAREPTA THERAPEUTICS INC financial statements.
Like other stocks, AB3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAREPTA THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAREPTA THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAREPTA THERAPEUTICS INC stock shows the strong buy signal. See more of SAREPTA THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.